vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and Ovintiv Inc. (OVV). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $2.1B, roughly 1.4× Ovintiv Inc.). Ovintiv Inc. runs the higher net margin — 46.1% vs -3.7%, a 49.7% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs -6.0%). Ovintiv Inc. produced more free cash flow last quarter ($489.0M vs $403.0M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs -7.2%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Ovintiv Inc. is a U.S. petroleum company based in Denver. The company was formed in 2020 through a restructuring of its Canadian predecessor, Encana.
BHC vs OVV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $2.1B |
| Net Profit | $-103.0M | $946.0M |
| Gross Margin | — | — |
| Operating Margin | 17.0% | 21.2% |
| Net Margin | -3.7% | 46.1% |
| Revenue YoY | 9.3% | -6.0% |
| Net Profit YoY | -205.1% | 1676.7% |
| EPS (diluted) | $-0.30 | $3.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $2.1B | ||
| Q3 25 | $2.7B | $2.0B | ||
| Q2 25 | $2.5B | $2.2B | ||
| Q1 25 | $2.3B | $2.4B | ||
| Q4 24 | $2.6B | $2.2B | ||
| Q3 24 | $2.5B | $2.2B | ||
| Q2 24 | $2.4B | $2.2B | ||
| Q1 24 | $2.2B | $2.4B |
| Q4 25 | $-103.0M | $946.0M | ||
| Q3 25 | $179.0M | $148.0M | ||
| Q2 25 | $148.0M | $307.0M | ||
| Q1 25 | $-58.0M | $-159.0M | ||
| Q4 24 | $98.0M | $-60.0M | ||
| Q3 24 | $-85.0M | $507.0M | ||
| Q2 24 | $10.0M | $340.0M | ||
| Q1 24 | $-64.0M | $338.0M |
| Q4 25 | 17.0% | 21.2% | ||
| Q3 25 | 23.1% | 13.5% | ||
| Q2 25 | 17.5% | 23.1% | ||
| Q1 25 | 12.2% | -3.7% | ||
| Q4 24 | 21.8% | 0.1% | ||
| Q3 24 | 12.7% | 24.2% | ||
| Q2 24 | 16.2% | 25.4% | ||
| Q1 24 | 13.1% | 20.7% |
| Q4 25 | -3.7% | 46.1% | ||
| Q3 25 | 6.7% | 7.3% | ||
| Q2 25 | 5.8% | 13.9% | ||
| Q1 25 | -2.6% | -6.7% | ||
| Q4 24 | 3.8% | -2.7% | ||
| Q3 24 | -3.4% | 23.3% | ||
| Q2 24 | 0.4% | 15.5% | ||
| Q1 24 | -3.0% | 14.2% |
| Q4 25 | $-0.30 | $3.64 | ||
| Q3 25 | $0.48 | $0.57 | ||
| Q2 25 | $0.40 | $1.18 | ||
| Q1 25 | $-0.16 | $-0.61 | ||
| Q4 24 | $0.24 | $-0.22 | ||
| Q3 24 | $-0.23 | $1.92 | ||
| Q2 24 | $0.03 | $1.27 | ||
| Q1 24 | $-0.17 | $1.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $280.0M |
| Total DebtLower is stronger | $20.8B | $5.2B |
| Stockholders' EquityBook value | $-554.0M | $11.2B |
| Total Assets | $26.4B | $20.4B |
| Debt / EquityLower = less leverage | — | 0.46× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $280.0M | ||
| Q3 25 | $1.3B | $25.0M | ||
| Q2 25 | $1.7B | $20.0M | ||
| Q1 25 | $1.1B | $8.0M | ||
| Q4 24 | $1.2B | $42.0M | ||
| Q3 24 | $719.0M | $9.0M | ||
| Q2 24 | $595.0M | $8.0M | ||
| Q1 24 | $733.0M | $5.0M |
| Q4 25 | $20.8B | $5.2B | ||
| Q3 25 | $21.0B | $5.2B | ||
| Q2 25 | $21.7B | $5.3B | ||
| Q1 25 | $21.5B | $5.5B | ||
| Q4 24 | $21.6B | $5.5B | ||
| Q3 24 | $21.5B | $5.9B | ||
| Q2 24 | $21.7B | $6.1B | ||
| Q1 24 | $22.1B | $6.2B |
| Q4 25 | $-554.0M | $11.2B | ||
| Q3 25 | $-565.0M | $10.2B | ||
| Q2 25 | $-764.0M | $10.4B | ||
| Q1 25 | $-1.2B | $10.1B | ||
| Q4 24 | $-1.3B | $10.3B | ||
| Q3 24 | $-1.2B | $10.7B | ||
| Q2 24 | $-1.2B | $10.3B | ||
| Q1 24 | $-1.1B | $10.3B |
| Q4 25 | $26.4B | $20.4B | ||
| Q3 25 | $26.8B | $19.4B | ||
| Q2 25 | $27.3B | $19.7B | ||
| Q1 25 | $26.4B | $19.6B | ||
| Q4 24 | $26.5B | $19.3B | ||
| Q3 24 | $26.5B | $19.9B | ||
| Q2 24 | $26.5B | $19.8B | ||
| Q1 24 | $26.9B | $19.8B |
| Q4 25 | — | 0.46× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.55× | ||
| Q2 24 | — | 0.59× | ||
| Q1 24 | — | 0.60× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $954.0M |
| Free Cash FlowOCF − Capex | $403.0M | $489.0M |
| FCF MarginFCF / Revenue | 14.4% | 23.8% |
| Capex IntensityCapex / Revenue | 3.3% | 22.6% |
| Cash ConversionOCF / Net Profit | — | 1.01× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $1.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $954.0M | ||
| Q3 25 | $405.0M | $812.0M | ||
| Q2 25 | $289.0M | $1.0B | ||
| Q1 25 | $211.0M | $873.0M | ||
| Q4 24 | $601.0M | $1.0B | ||
| Q3 24 | $405.0M | $1.0B | ||
| Q2 24 | $380.0M | $1.0B | ||
| Q1 24 | $211.0M | $659.0M |
| Q4 25 | $403.0M | $489.0M | ||
| Q3 25 | $314.0M | $268.0M | ||
| Q2 25 | $190.0M | $492.0M | ||
| Q1 25 | $96.0M | $256.0M | ||
| Q4 24 | $495.0M | $468.0M | ||
| Q3 24 | $334.0M | $484.0M | ||
| Q2 24 | $302.0M | $398.0M | ||
| Q1 24 | $129.0M | $68.0M |
| Q4 25 | 14.4% | 23.8% | ||
| Q3 25 | 11.7% | 13.3% | ||
| Q2 25 | 7.5% | 22.2% | ||
| Q1 25 | 4.2% | 10.8% | ||
| Q4 24 | 19.3% | 21.4% | ||
| Q3 24 | 13.3% | 22.2% | ||
| Q2 24 | 12.6% | 18.1% | ||
| Q1 24 | 6.0% | 2.8% |
| Q4 25 | 3.3% | 22.6% | ||
| Q3 25 | 3.4% | 26.9% | ||
| Q2 25 | 3.9% | 23.5% | ||
| Q1 25 | 5.1% | 26.0% | ||
| Q4 24 | 4.1% | 25.3% | ||
| Q3 24 | 2.8% | 24.7% | ||
| Q2 24 | 3.2% | 28.4% | ||
| Q1 24 | 3.8% | 24.8% |
| Q4 25 | — | 1.01× | ||
| Q3 25 | 2.26× | 5.49× | ||
| Q2 25 | 1.95× | 3.30× | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.13× | — | ||
| Q3 24 | — | 2.02× | ||
| Q2 24 | 38.00× | 3.00× | ||
| Q1 24 | — | 1.95× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
OVV
| Product And Service Revenue | $1.7B | 84% |
| Sales Of Purchased Product | $338.0M | 16% |
